Загрузка...
Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
BACKGROUND: The current standard of care for the management of patients with newly diagnosed glioblastoma (GBM) includes maximal safe resection followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ). While it is well established that TMZ has better efficacy in patients with MG...
Сохранить в:
| Опубликовано в: : | Neurooncol Adv |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7596890/ https://ncbi.nlm.nih.gov/pubmed/33150334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa082 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|